| ID | 1188 |
| Name of the vaccine | Sf2aWC |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Formalin-inactivated whole cell Shigella flexneri 2a killed vaccine. |
| Name of the manufacturer | PATH |
| Name of the manufacturing country | United States |
| Year of manufacture | 2019 |
| Clinical Phase status | Clinical - Withdrawn |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Sterile liquid suspension |
| Dosage | Three doses. |
| Mechanism of action | IgA and IgG responses to LPS, Th1 and Th17 cytokines. |
| Route of administration | Oral |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | dmLT |
| Repurposing | NA |
| Side effects of vaccine | Loose stools, diarrhoea, abdominal pain, bloating, defecation urgency, nausea, vomiting, headache, malaise, chills, myalgia, reactive arthritis and constipation. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 26865592 |
| Clinical trial number | NCT03038243 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|